Company: HCWB
Filing Date: 2025-02-21
Form Type: DEF 14A
Source: 0001193125-25-032115
Chunk: 94

Company: HCW Biologics Inc.
Filing Date: 2025-02-21
Form: DEF 14A
Chunk 94
---
 to an affiliate of such Investor.

10. .

No provision of this Agreement may be (i) amended other than by a written instrument signed by both parties hereto or (ii) waived
other than in a written instrument signed by the party against whom enforcement of such waiver is sought. Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy,
shall not operate as a waiver thereof.

- A-40 -

11. .

a. A Person is deemed to be a holder of Registrable Securities whenever such Person owns or is deemed to own of record such Registrable
Securities. If the Company receives conflicting instructions, notices or elections from two or more Persons with respect to the same Registrable Securities, the Company shall act upon the basis of instructions, notice or election received from the
registered owner of such Registrable Securities.

b. Any notices, consents, waivers or other communications required or permitted to be
given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by email (provided confirmation of transmission is mechanically
or electronically generated and kept on file by the sending party); or (iii) one (1) business day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same. The
addresses for such communications shall be:

If to the Company:

2929 North Commerce Parkway

Miramar, FL 33025

Attention:
Hing C. Wong and Nicole Valdivieso, Esq.

E-mail: hingwong@hcwbiologics.com and
legal@hcwbiologics.com

With a mandatory copy (which shall not constitute notice) to:

Clark Hill

130 East Randolph
Street

Suite 3900

Chicago,
IL 60601

Attention: James F. Groth

Email: jgroth@clarkhill.com

If
to the Investor:

Square Gate Capital Master Fund, LLC -

Series 4

40 Wall Street

Floor 28, Suite 2728

New York,
NY 10005

E-mail: eloc@squaregatecapital.com

Attention: Christopher Perugini, Managing Partner

with a mandatory copy to (that shall not constitute notice)

Lucosky Brookman LLP

101 Wood
Avenue South

Woodbridge, NJ 08830

E